Sanjay Dandamudi1, Joshua Slusser2, Douglas W Mahoney2, Margaret M Redfield3, Richard J Rodeheffer3, Horng H Chen4. 1. The Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois. 2. The Division of Biomedical Statistics and Informatics, Mayo Clinic and Foundation, Rochester, Minnesota. 3. The Department of Medicine, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, Minnesota. 4. The Department of Medicine, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, Minnesota. Electronic address: chen.horng@mayo.edu.
Abstract
BACKGROUND:Diabetic cardiomyopathy defined as either systolic or diastolic dysfunction in otherwise healthy diabetic persons is not clearly understood. The prevalence and outcomes of this disease in a community-based population have not been defined. METHODS AND RESULTS: Cross-sectional survey of 2042 randomly selected residents of Olmsted County, Minnesota, aged 45 years or older between June 1997 and September 2000. All patients underwent Doppler echocardiographic assessment of systolic and diastolic function. Diabetic cardiomyopathy was defined in a person with diabetes and any systolic or at least moderate diastolic dysfunction without a history of coronary disease, hypertension, significant valvular disease, or congenital heart disease. The diagnosis of diabetic cardiomyopathy was made in 23 people, corresponding to a community population prevalence rate of 1.1%. Among diabetic patients, 16.9% met criteria for diabetic cardiomyopathy and 54.4% had diastolic dysfunction. Diabetes was associated with a 1.9-fold increase in risk of any left ventricular dysfunction, a 1.7-fold increase in risk of diastolic dysfunction, and a 2.2-fold increase in risk of systolic dysfunction. Among patients with diabetic cardiomyopathy, the cumulative probability of death was 18%, development of heart failure was 22%, and development of death or heart failure was 31% at 9 years. CONCLUSION:Diabetic cardiomyopathy is relatively common in the community with a prevalence of 1.1%. The morbidity and mortality of patients with diabetic cardiomyopathy is high.
RCT Entities:
BACKGROUND:Diabetic cardiomyopathy defined as either systolic or diastolic dysfunction in otherwise healthy diabeticpersons is not clearly understood. The prevalence and outcomes of this disease in a community-based population have not been defined. METHODS AND RESULTS: Cross-sectional survey of 2042 randomly selected residents of Olmsted County, Minnesota, aged 45 years or older between June 1997 and September 2000. All patients underwent Doppler echocardiographic assessment of systolic and diastolic function. Diabetic cardiomyopathy was defined in a person with diabetes and any systolic or at least moderate diastolic dysfunction without a history of coronary disease, hypertension, significant valvular disease, or congenital heart disease. The diagnosis of diabetic cardiomyopathy was made in 23 people, corresponding to a community population prevalence rate of 1.1%. Among diabeticpatients, 16.9% met criteria for diabetic cardiomyopathy and 54.4% had diastolic dysfunction. Diabetes was associated with a 1.9-fold increase in risk of any left ventricular dysfunction, a 1.7-fold increase in risk of diastolic dysfunction, and a 2.2-fold increase in risk of systolic dysfunction. Among patients with diabetic cardiomyopathy, the cumulative probability of death was 18%, development of heart failure was 22%, and development of death or heart failure was 31% at 9 years. CONCLUSION:Diabetic cardiomyopathy is relatively common in the community with a prevalence of 1.1%. The morbidity and mortality of patients with diabetic cardiomyopathy is high.
Authors: S R Ommen; R A Nishimura; C P Appleton; F A Miller; J K Oh; M M Redfield; A J Tajik Journal: Circulation Date: 2000-10-10 Impact factor: 29.690
Authors: J S Gottdiener; A M Arnold; G P Aurigemma; J F Polak; R P Tracy; D W Kitzman; J M Gardin; J E Rutledge; R C Boineau Journal: J Am Coll Cardiol Date: 2000-05 Impact factor: 24.094
Authors: J E Liu; V Palmieri; M J Roman; J N Bella; R Fabsitz; B V Howard; T K Welty; E T Lee; R B Devereux Journal: J Am Coll Cardiol Date: 2001-06-01 Impact factor: 24.094
Authors: J N Bella; R B Devereux; M J Roman; V Palmieri; J E Liu; M Paranicas; T K Welty; E T Lee; R R Fabsitz; B V Howard Journal: Am J Cardiol Date: 2001-06-01 Impact factor: 2.778
Authors: A Ilercil; R B Devereux; M J Roman; M Paranicas; M J O'grady; T K Welty; D C Robbins; R R Fabsitz; B V Howard; E T Lee Journal: Am Heart J Date: 2001-06 Impact factor: 4.749
Authors: V Palmieri; J N Bella; D K Arnett; J E Liu; A Oberman; M Y Schuck; D W Kitzman; P N Hopkins; D Morgan; D C Rao; R B Devereux Journal: Circulation Date: 2001-01-02 Impact factor: 29.690
Authors: R B Devereux; M J Roman; M Paranicas; M J O'Grady; E T Lee; T K Welty; R R Fabsitz; D Robbins; E R Rhoades; B V Howard Journal: Circulation Date: 2000-05-16 Impact factor: 29.690
Authors: Benjamin Steinhorn; Juliano L Sartoretto; Andrea Sorrentino; Natalia Romero; Hermann Kalwa; E Dale Abel; Thomas Michel Journal: Free Radic Biol Med Date: 2017-09-14 Impact factor: 7.376
Authors: Timothy J Roberts; Andrew T Burns; Richard J MacIsaac; Andrew I MacIsaac; David L Prior; André La Gerche Journal: J Appl Physiol (1985) Date: 2019-05-02
Authors: Marilen Federico; Enrique L Portiansky; Leandro Sommese; Francisco J Alvarado; Paula G Blanco; Carolina N Zanuzzi; John Dedman; Marcia Kaetzel; Xander H T Wehrens; Alicia Mattiazzi; Julieta Palomeque Journal: J Physiol Date: 2017-03-02 Impact factor: 5.182
Authors: Maxim Verboven; Lisa Van Ryckeghem; Jamal Belkhouribchia; Paul Dendale; Bert O Eijnde; Dominique Hansen; Virginie Bito Journal: Sports Med Date: 2019-02 Impact factor: 11.136